276 related articles for article (PubMed ID: 18549872)
1. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
Davidson MH; Corson MA; Alberts MJ; Anderson JL; Gorelick PB; Jones PH; Lerman A; McConnell JP; Weintraub HS
Am J Cardiol; 2008 Jun; 101(12A):51F-57F. PubMed ID: 18549872
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Anderson JL
Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
[TBL] [Abstract][Full Text] [Related]
3. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
4. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
5. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
7. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes.
Noto H; Chitkara P; Raskin P
J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk?
Lee JH; Engler MM
Prog Cardiovasc Nurs; 2009 Dec; 24(4):181-9. PubMed ID: 20002343
[TBL] [Abstract][Full Text] [Related]
9. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM
J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS
Prev Cardiol; 2010; 13(3):130-4. PubMed ID: 20626668
[TBL] [Abstract][Full Text] [Related]
11. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease.
Epps KC; Wilensky RL
J Intern Med; 2011 Jan; 269(1):94-106. PubMed ID: 21054587
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein-associated phospholipase A2 and risk of stroke.
Gorelick PB
Am J Cardiol; 2008 Jun; 101(12A):34F-40F. PubMed ID: 18549870
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Carlquist JF; Muhlestein JB; Anderson JL
Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Khakpour H; Frishman WH
Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473
[TBL] [Abstract][Full Text] [Related]
15. [Lipoprotein associated phospholipase A2].
Rubinstein A; Izkhakov E
Harefuah; 2011 Feb; 150(2):136-40, 205. PubMed ID: 22164942
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor?
Lerman A; McConnell JP
Am J Cardiol; 2008 Jun; 101(12A):11F-22F. PubMed ID: 18549867
[TBL] [Abstract][Full Text] [Related]
17. Effects of V279F in the Lp-PLA(2) gene on markers of oxidative stress and inflammation in Koreans.
Paik JK; Chae JS; Jang Y; Kim JY; Kim OY; Jeong TS; Lee SH; Lee JH
Clin Chim Acta; 2010 Apr; 411(7-8):486-93. PubMed ID: 20080080
[TBL] [Abstract][Full Text] [Related]
18. Identifying the vulnerable patient with rupture-prone plaque.
Weintraub HS
Am J Cardiol; 2008 Jun; 101(12A):3F-10F. PubMed ID: 18549869
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists.
Davidson MH; Ballantyne CM; Jacobson TA; Bittner VA; Braun LT; Brown AS; Brown WV; Cromwell WC; Goldberg RB; McKenney JM; Remaley AT; Sniderman AD; Toth PP; Tsimikas S; Ziajka PE; Maki KC; Dicklin MR
J Clin Lipidol; 2011; 5(5):338-67. PubMed ID: 21981835
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
Toth PP; McCullough PA; Wegner MS; Colley KJ
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):425-38. PubMed ID: 20222820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
